Royalty Pharma (RPRX) Cash from Operations (2019 - 2026)

Royalty Pharma has disclosed Cash from Operations across 8 years of filings, most recently posting 718233000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 718233000.0, up 20.49% year-over-year; the trailing twelve-month figure through Mar 2026 was 2611980000.0 (down 3.28% YoY), and the FY2025 annual result was 2489823000.0, down 10.08% from the prior year.
• Cash from Operations came in at 718233000.0 for Q1 2026 at Royalty Pharma, down from 827148000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1033837000.0 in Q1 2023 to a low of 363984000.0 in Q2 2025.
• The 5-year median for Cash from Operations is 658209000.0 (2024), against an average of 653460235.29.
• Across the five-year window, Cash from Operations jumped 124.62% in 2023 and slumped 44.7% in 2025, its largest moves.
• Royalty Pharma's Cash from Operations stood at 569931000.0 in 2022, then jumped by 35.57% to 772628000.0 in 2023, then declined by 3.9% to 742525000.0 in 2024, then advanced by 11.4% to 827148000.0 in 2025, then dropped by 13.17% to 718233000.0 in 2026.
• The last three Cash from Operations figures came in at 718233000.0 (Q1 2026), 827148000.0 (Q4 2025), and 702615000.0 (Q3 2025), per Business Quant data.